The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis.

amlitelimab IV (SAR445229) - Sanofi

STAR-0310 - Astria Therap

APG-279 - Apogee Therap

IMG-007 - ImageneBio

rocatinlimab (AMG 451) - Amgen

APG990 - Apogee Therap

telazorlimab (ISB 830) - Astria Therap

http://www.ncbi.nlm.nih.gov/pubmed/41535648

Adam Mohamed; Amir Mohamed; David Oliveira Dos Santos; José Miguel Alvarenga; Tiago Torres

Jan 15, 2026